Research Analysts Set Expectations for CGTX FY2024 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Investment analysts at Brookline Capital Management issued their FY2024 earnings per share estimates for Cognition Therapeutics in a report issued on Monday, January 27th. Brookline Capital Management analyst T. Bussian forecasts that the company will earn ($0.83) per share for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.86) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($0.95) EPS.

Other equities analysts have also issued reports about the stock. Chardan Capital reiterated a “buy” rating and set a $11.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 19th. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $1.00 to $1.50 in a report on Thursday, December 19th. Finally, HC Wainwright lifted their target price on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $8.30.

Cognition Therapeutics Stock Up 6.9 %

Shares of NASDAQ CGTX opened at $0.76 on Wednesday. Cognition Therapeutics has a 12-month low of $0.34 and a 12-month high of $2.95. The firm’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.70. The company has a market cap of $31.53 million, a price-to-earnings ratio of -0.78 and a beta of 0.95.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CGTX. Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics during the third quarter worth $27,000. Mercer Global Advisors Inc. ADV boosted its holdings in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after buying an additional 24,050 shares during the last quarter. Sigma Planning Corp grew its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after buying an additional 25,050 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Cognition Therapeutics in the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.